- Home
- Special Topics
- Disease areas
- Cancer
This page brings together the Agency's latest information on cancer. It lists:
the ten newest and recently updated medicines authorised for the treatment of cancer in the European Union (EU);
the most recent opinions on anti-cancer medicines that are pending authorisation by the European Commission (EC);
the latest cancer-related news and press releases;
the Agency's events on cancer-related topics.
New and recently updated medicines
-
02/07/2012
human
-
05/12/2012
human
-
13/09/2012
human
-
17/08/2011
human
-
31/12/2009
human
-
25/02/2013
human
-
15/04/2013
human
-
02/07/2012
human
-
04/02/2013
human
-
19/07/2011
human
Opinions pending EC decision
-
30/05/2013
human
-
30/05/2013
human
-
25/04/2013
human
-
21/03/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
21/03/2013
human
-
21/03/2013
human
-
21/02/2013
human
-
21/02/2013
human
News
31/05/2013
European Medicines Agency recommends approval of pomalidomide for the treatment of multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pomalidomide Celgene (pomalidomide) to treat patients with multiple myeloma. ... Read more
31/05/2013
European Medicines Agency recommends approval of pomalidomide for the treatment of multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pomalidomide Celgene (pomalidomide) to treat patients with multiple myeloma. ... Read more
26/04/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013
This page provides an overview of the opinions adopted at the April 2013 meeting of the CHMP and other important outcomes. ... Read more
22/03/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2013
This page provides an overview of the opinions adopted at the March 2013 meeting of the CHMP and other important outcomes. ... Read more
22/02/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 February 2013
This page provides an overview of the opinions adopted at the February 2013 meeting of the CHMP and other important outcomes. ... Read more
22/02/2013
Public consultation opens on standard paediatric investigation plans for two types of cancer in children
The European Medicines Agency has opened a public consultation on two standard paediatric investigation plans (PIPs) for two specific types of cancer with unmet medical needs in children, acute myeloid leukaemia and rhabdomyosarcoma. ... Read more
01/02/2013
World Cancer Day: 4 February 2013
The European Medicines Agency supports World Cancer Day, which is taking place on Monday 4 February 2013. ... Read more
18/01/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013
This page provides an overview of the opinions adopted at the January 2013 meeting of the CHMP and other important outcomes. ... Read more
11/01/2013
European Medicines Agency updates guideline on evaluation of anticancer medicines
The European Medicines Agency has finalised the revision of its guideline on the evaluation of anticancer medicinal products. ... Read more
20/12/2012
Only For Children Pharmaceuticals withdraws its marketing-authorisation application for Loulla (mercaptopurine)
The European Medicines Agency has been formally notified by Only For Children Pharmaceuticals of its decision to withdraw its application for a centralised marketing authorisation for the medicine Loulla (mercaptopurine), 10 mg/ml, tablets and solution for oral suspension. ... Read more
Events
02/05/2012
EMA
Workshop on health-related quality of life in oncology
The workshop on health-related quality of life (HRQoL) in oncology aims to bring together relevant experts and discuss HRQoL issues with a focus on available instruments (including patient-reported outcomes [PRO]) and their utilisation in oncology clinical trials. The intention is to generate a HRQoL/PRO appendix to the anticancer medicines guideline. Registration by invitation only. ... Read more
03/12/2010
PDCO
High-grade glioma expert group
The European Medicines Agency is holding this expert meeting to understand and discuss how anti-cancer medicines should be developed to treat children with high-grade glioma, a disease with a dismal prognosis and high unmet needs. Recent biological and clinical data, as well as experience from paediatric trials, is being discussed. Preliminary consequences for paediatric trials and further questions are being identified. ... Read more